entertainment -WSS

entertainment

author：leisure time 2025-10-01 22:58:50 - browse：7

A vial of Tofersen injection on the left of its box — The ALS drug tofersen is marketed as Qalsody in the U.S. Biogen

LONDON — Neurologists and patient advocates are up in arms over a policy decision by a U.K. health agency that they say will imperil access to an ALS treatment that’s available in the U.S. and on its way to approval in the European Union.

The medicine in question, Biogen’s tofersen, is designed to treat a rare genetic form of the neurodegenerative disease, accounting for some 2% of all ALS cases. And the issue is how the U.K.’s cost-effectiveness agency has said it would assess the costs and benefits of the therapy.

The agency, the National Institute for Health and Care Excellence, or NICE, has a special pathway for drugs for very rare diseases, which advocates and doctors argue is the route through which tofersen should be reviewed. But NICE has indicated it would review the drug through its standard process, saying it’s because ALS as a whole does not count as a “very rare” disease. That sets a higher bar to clear.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： As pharma fights Medicare drug negotiation, hospitals, docs silent

WSS

Radiation, mainstay of cancer treatment, begins a fade

In science, is the line between industry and academia shifting?

Average age of first period drops to 11.9 years, study shows

Do more moles mean more problems? Not so, says new study

Prosthetic arm enables patients to feel the objects they grip

Report: NIH

explore

entertainment

focus

DIEP, the 'gold standard' of breast reconstruction, is under threat

As pharma fights Medicare drug negotiation, hospitals, docs silent

Psychedelics group wrestles with new pharma identity

Prosthetic arm enables patients to feel the objects they grip

23andMe had bad news about my health. I wish a person had delivered it

AI used to predict Covid

Activists slam private health insurers over coverage restrictions

Heat waves linked to early deliveries, preterm births in new study

Sports medicine is finally prioritizing gender equality

AstraZeneca challenges Medicare drug negotiation program

explore

Do more moles mean more problems? Not so, says new study

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

AstraZeneca challenges Medicare drug negotiation program

Study finds new variant for Parkinson’s in African populations

How to make AI work for medicine

Report: NIH

Wikipedia

entertainment

hotspot

Wikipedia